SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

VIMIZIM

BMRN·BIOMARIN PHARMACEUTICAL INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed since February 2014.
Why 4/10
VIMIZIM is an already-approved, marketed drug with no pending PDUFA, pivotal readout, or other hard binary catalyst scheduled in the next ~12 months. It is one of several revenue drivers within BioMarin's diversified portfolio. Per the rubric, an approved drug with no imminent regulatory decision scores 3-5; a default of 4 applies.
Actionable Insight NEUTRAL

VIMIZIM is a mature, approved revenue driver with no binary catalyst ahead. Watch for any biosimilar entry (projected exclusivity loss around 2026-2029) and for quarterly revenue trends in BioMarin's Metabolic Conditions segment, which includes VIMIZIM alongside newer acquired assets. The next major BioMarin catalyst is the VOXZOGO PDUFA for hypochondroplasia on May 30, 2027, not VIMIZIM.

Price Chart

Loading chart...

Executive Summary

VIMIZIM (elosulfase alfa) is BioMarin Pharmaceutical's enzyme replacement therapy for Morquio A syndrome (MPS IVA), a rare genetic lysosomal storage disorder. FDA-approved in February 2014, it is the first and only approved treatment for this indication. VIMIZIM generated approximately $740 million in net product revenue in 2024, making it one of BioMarin's top three products. In Q3 2026, BioMarin's Metabolic Conditions segment (which includes VIMIZIM) grew 44% year-over-year, with higher VIMIZIM revenue cited as a contributor. The drug faces eventual biosimilar competition risk as exclusivity protections expire, but currently enjoys a monopoly position in a small, durable patient population requiring chronic weekly dosing. BioMarin (BMRN, Nasdaq) is a diversified rare-disease biotech with multiple approved products; VIMIZIM is a mature commercial asset with no near-term binary catalyst.

How It Works

VIMIZIM is an enzyme replacement therapy (ERT) for Morquio A syndrome, a rare genetic disorder where patients lack a working version of the enzyme GALNS. Without this enzyme, certain sugar molecules (GAGs) build up in cells and damage organs, bones, and connective tissue. VIMIZIM is a lab-made version of the missing enzyme, given as a weekly intravenous infusion, that helps break down the accumulated waste material.

Trial Status

VIMIZIM is fully approved and commercially marketed. Post-marketing studies (e.g., NCT02294877, an observational long-term safety and effectiveness study) are ongoing or completed. No new pivotal trials are underway for this indication.

The Two-Sided Case

▲ Bull Case5
VIMIZIM is the first and only FDA-approved enzyme replacement therapy for Morquio A syndrome (MPS IVA), with no approved competitor, giving it a durable market position.
BioMarin's Q3 2026 earnings reported Metabolic Conditions revenue (which includes VIMIZIM) grew 44% Y/Y, with higher VIMIZIM revenue cited as a contributor, and patient numbers increased across all Metabolic Conditions therapies.
VIMIZIM generated approximately $740M in net product revenue in 2024 (per BioMarin's 10-K), making it one of the company's top three products and a significant cash flow contributor.
Chronic weekly dosing creates a sticky, recurring revenue base from a small but durable global patient population with a life-long treatment need.
Analyst consensus on BMRN is bullish: 27 analysts give a mean price target of $91.56 (57.4% implied upside from $58.16), with 27 Buy/Strong Buy ratings vs 8 Hold and 0 Sell.
▼ Bear Case4
Orphan drug exclusivity expired in 2021; projected loss of broader exclusivity around February 2026 (per CliffBio's 12-year biologic estimate), opening the door to eventual biosimilar competition.
VIMIZIM revenue can be lumpy due to timing of large government orders outside the U.S., as noted in BioMarin's Q2 2026 earnings release.
BioMarin's Q3 2026 earnings (Nov 2, 2026) showed a GAAP net loss of -$123M and a ~40% cut to full-year Non-GAAP EPS guidance, driven by acquisition-related charges, creating headline risk for the whole portfolio.
Early-stage gene therapy research for Morquio A (e.g., Nemours/FNIH Bespoke Gene Therapy Consortium) could eventually threaten the ERT market if successful.

Upcoming Catalysts

  • No VIMIZIM-specific binary catalysts are scheduled. BioMarin's next major catalyst is the VOXZOGO PDUFA target action date for hypochondroplasia on May 30, 2027.
  • Quarterly revenue trends in the Metabolic Conditions segment (which includes VIMIZIM) will be reported with BioMarin's Q4 2026 earnings, expected in February 2027.
  • Any biosimilar development or patent challenge announcements would be a negative catalyst for VIMIZIM's long-term revenue outlook.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report

Sources · 11

Hover a chip for the title
1 biomarin.com2 biomarin.com3 sec.gov4 marketbeat.com5 benzinga.com6 biomarin.com7 cliffbio.com8 drugpatentwatch.com9 en.wikipedia.org10 biocosm.io11 hcp.biomarin.com